The MSC2011 Conference on Regenerative Medicine and Adult Stem Cell Therapy will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. Become an active part of MSC2011 today—let us know if you have suggestions for speakers or topics, or would like to be involved in planning and implementation. Email registration@mscconference.net or call 1-216-368-2079 to submit your ideas.
News
July 06, 2010
US Scientists Succesful In Creating HIV-Resistant Cells Link to article
July 06, 2010
New Stem Cell Therapy for Parkinson's Hailed as "A Small Miracle" Link to article
July 01, 2010
Gene Regulating Human Brain Development Identified Link to article
Stem Cell Types at the Center for Stem Cell and Regenerative Medicine
Due to the impressive breadth of investigator
expertise, the scope of adult and pluripotent stem cell types
under study within the Center is comprised of the following
types:
ASC
Adipose Stem Cells
CSC
Cochlear Stem Cells
CTP
Connective Tissue Progenitor
Cells
ESC
Embryonic Stem Cells
HSC
Hematopoietic Stem Cells
HB1
Hemangioblast (AC133) derived from umbilical
cord blood
iPS
Induced Pluripotent Stem Cells
MAPC
Multi-potent Adult Stem Cells
MSC
Mesenchymal Stem Cells
NSC
Neural Stem Sells/oligodendrocyte progenitors
SKMB
Skeletal Myoblasts
UCB
Umbilical Cord Blood Derived Stem
Cells
This collection of stem cells is being investigated
for therapeutic uses in musculoskeletal, cardiovascular,
hematopoietic and neurological disorders.
This collection of stem cells also is being
investigated for therapeutic uses in musculoskeletal,
cardiovascular, hematopoietic and neurological
disorders.
Cardiovascular and vascular ESC, HB1, HSC, iPS, MAPC, SKMB, UCB Myocardial regeneration with cell
homing, differentiation and regeneration, vascular
remodeling -- for ischemic, congestive and dilated
cardiomyopathy.
Hematopoietic and cancer ESC, HB1, HSC, iPS, MSC, UCB UCB (umbilical cord blood) stem
cell expansion and transplantation, cytokine
directed differentiation for GVL (graft vs.
leukemia), marrow reconstitution and stem cell
selection, HSC gene transfer, MSC modulation of
GVHD (graft vs. host disease), -- for curing
cancer allogeneic transplantation, correction of
genetic diseases and protection from
chemotherapy.
Neurodegenerative and
neurological MAPC, NSC Cell
implantation into brain and spinal cord for
neuronal or glial replacement therapy in
Neurodegenerative disorders – Huntington’s
disease, multiple sclerosis, amyotropic lateral
sclerosis and spinal cord injury.
Orthopedic and
Musculoskeletal CTP, MAPC, MSC, SKMB Bone and cartilage repair, MSC homing
factors, myoblast homing using surface molecule
“painting” -- for fractures, joint disease,
muscular
dystrophy.
Areas of Research at the Clinical Tissue Engineering Center (CTEC)
CTEC’s mission is to accelerate the rate at which new tissue engineering discoveries and inventions are translated into new treatments, products, and business opportunities in Ohio. CTEC investigators focus on translating new technologies in tissue engineering into methods, devices, diagnostic tools and therapeutics to treat osteoarthritis, fractures and bone deficiencies, osteoporosis, traumatic and degenerative tendon rupture and acute and chronic soft tissue wounds. In addition, the Center is establishing a collaborative network of academic and commercial partnerships for bringing these new technologies to market in the form of commercial products for treatment of these human diseases and conditions.
